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Summary Genetic studies have been made in two cases of primary choriocarcinoma from patients in whom
the antecedent pregnancy was a hydatidiform mole. Restriction fragment length polymorphisms of the DNA
from the tumour, the patient and her partner were examined and in both cases the tumours were shown to be
androgenetic in origin, having only paternal polymorphisms. While one tumour was shown to be
heterozygous, two different paternal alleles being demonstrated with some probes, the other tumour was
shown to be homozygous for all informative polymorphisms examined. Thus choriocarcinoma can follow
complete hydatidiform mole which may be either heterozygous or homozygous.
Choriocarcinoma, a tumour arising from placental tropho-
blast may follow any type of pregnancy. However,
pregnancies with a hydatidiform mole (HM), an abnormal
conception characterised by hydropic swelling of the
placental villi and hyperplasia of the villous trophoblast, are
in the order of a thousand times more likely to progress to
choriocarcinoma than non molar pregnancies (Bagshawe et
al., 1973). Approximately ten per cent of HM do not resolve
spontaneously following evacuation (WHO, 1983). About a
third of these cases will be choriocarcinomas (Bagshawe,
1969), the remaining cases being invasive mole which,
though technically benign, can prove fatal through events
such as uterine perforation.
In an attempt to identify those HM which are likely to
progress to trophoblastic tumours, several studies have been
made of the genetic origin of molar pregnancies and related
to the subsequent clinical history of the patients (Vassilakos
et al., 1977; Lawler et al., 1979; Kajii, 1980; Lawler et al.,
1982a & b; Wake et al., 1984). On the basis of genetic origin
HM have been divided into three types. Approximately 25%
of HM ascertained clinically are partial HM (Lawler et al.,
1982a). They are triploid (Szulman & Surti, 1978), the
additional set of chromosomes generally being paternally
derived (Lawler et al., 1982a; Jacobs et al., 1982). Partial
HM have not so far been demonstrated to be associated with
the development of choriocarcinoma (Vassilakos et al., 1977;
Lawler et al., 1982a; Szulman & Surti, 1985; Lawler &
Fisher, 1987). The second type of HM which can be
classified pathologically is the complete HM (CHM). CHM
are genetically diploid but are unusual in that they are
androgenetic, all chromosomes being paternally derived
(Kajii & Ohama, 1977; Wake et al., 1978), although the
cytoplasm in these conceptions has been shown to be
maternally derived as in normal conceptions (Wallace et al.,
1982; Edwards et al., 1984). CHM may have one of two
different origins. The majority, about 90%, are homozygous
(Kajii & Ohama, 1977; Wake et al., 1978; Jacobs et al., 1978;
Lawler et al., 1979), arising from duplication of a haploid
sperm (Lawler et al., 1979; Jacobs et al., 1980). The rare type
of CHM arises by dispermy, the fertilisation of an anucleate
egg by two sperm (Ohama et al., 1981), and are therefore
heterozygous. Within the CHM it has been suggested that
the heterozygous CHM has the more malignant potential
(Kajii, 1980; Wake et al., 1981; Wake et al., 1984).
Few cases of choriocarcinoma have been studied
genetically. In eight cases where the origin has been
determined using chromosomal and enzyme polymorphisms
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(Wake et al., 1981; Sasaki et al., 1982; Sheppard et al., 1985;
Lawler & Fisher, 1986) all have been shown to be hetero-
zygous including the three cases where the antecedent
pregnancy was a HM. These results lend support to the
hypothesis that heterozygous CHM are more likely to
progress to choriocarcinoma.
We report here studies of the origin of two further cases
of choriocarcinoma where the antecedent pregnancy was a
HM.
Examining restriction fragment length polymorphisms of
the DNA (RFLPs) from these tumours we have shown that
although one tumour was heterozygous the other was homo-
zygous demonstrating that choriocarcinoma may follow both
homozygous and heterozygous CHM.
Materials and methods
Patient MA, was a Caucasian, 29 years old at the time of
diagnosis of choriocarcinoma, with an obstetric history of
four spontaneous abortions over a period of ten years. The
fourth pregnancy was diagnosed as a HM. Six weeks
following the termination of the molar pregnancy a patho-
logical diagnosis of primary choriocarcinoma was made on
uterine currettings.
Patient FS, of Arabic origin, was 42 years old at the time
choriocarcinoma was diagnosed. She had an obstetric history
of six live births and three abortions (3rd, 5th & 9th
pregnancy). Her tenth pregnancy, a HM, was evacuated six
years prior to the patient being admitted for currettage for
vaginal bleeding. A hysterectomy was performed and a
histological diagnosis of choriocarcinoma made.
Fresh tissue from the tumours and ten mls of heparinised
blood from the patients and their spouses were collected for
genetic studies. DNA was prepared using standard
techniques from the tumour tissue and parental blood. Five
to 8,g of DNA from each sample were digested with an
appropriate restriction enzyme. The restriction fragments
were separated by gel electrophoresis and transferred to
Gene Screen plus by Southern blotting. Hybridisation was
carried out with a panel of locus-specific minisatellite probes,
)MSI, pAg3, )MS31, AMS43, (Wong et al., 1986, 1987),
probes for single copy gene sequences., pHM6 (Schmidt et
al., 1984), pCGa (Boothby et al., 1981), pHC36 (Hoppener
et al., 1984), plO-5 (Schwartz et al., 1985), and a probe for Y
chromosome-specific sequences, CY84 (Wolfe et al., 1985).
Probes selected were specific for unlinked sequences of DNA
(eight of the nine probes used being for sequences on
different chromosomes) which showed a high degree of
polymorphism (HGM8). Localisation of the informative
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probes used and the restriction endonucleases with which the
polymorphisms were demonstrated are shown in Table I.
Following hybridisation filters were washed to a stringency
of 0.1XSSC, 0.1% SDS at 65°C and then exposed to film
for 2-7 days at -70°C.
Banding patterns produced by digestion of DNA followed
by hybridisation with the panel of probes were examined and
the RFLPs of the tumour tissue compared with that of its
parents.
Results
(a) Restriction fragment length polymorphisms
RFLPs of the parental and tumour DNA are summarised in
Table I.
Patient MA
Analysis of parental RFLPs following hybridisation with
AMS1, )MS31, AMS43 and pCGa showed maternal and
paternal patterns to be completely different (Table I; Figure
1). Examination of RFLPs in the tumour tissue identified
with these probes showed that in all cases the major band in
the sample, representing the tumour tissue, was androgenetic,
having been inherited from the father. Following hybridisa-
tion with pCGoa, )MS1 and pAg3, minor bands were seen
corresponding to maternal alleles. These bands represent
DNA derived from the small number of infiltrating host cells
which are present in the tumour tissue. Results with other
autosomal probes, pAg3 and pHC36, were uninformative
with respect to paternal origin of the tissue, the parents
having an allele in common (Table I, Figure 1).
Fives probes, pHC36, ,MS1, AMS31, pAg3 and 1MS43,
detected two different alleles in the paternal genome (Table
I; Figure 1). Examination of the RFLPs identified with these
probes in the tumour showed the tumour to be homozygous
in each instance.
Because of the small amount of tumour material available
it was not possible to obtain equal loading of parental and
tumour DNA in all cases and thus accurate studies of gene
dosage in the tumours have not been attempted. The filter
initially hybridised with pAg3 was subsequently hybridised to
AMS31 while a second filter was hybridised with .MS43 and
then )MSI. The relative strength of the tumour band
compared to the paternal bands for a particular filter was
the same whichever probe was used suggesting that there was
a similar dose of the alleles studied in the tumour.
Patient FS
The androgenetic origin of tumour FS was demonstrated by
RFLPs identified with )MSl and pAg3 (Table I).
Hybridisation with pAg3 also demonstrated the heterozygous
nature of the tumour (Figure 2), both paternal bands being
present in the tumour tissue. A minor band, representing
maternal DNA from host cells infiltrating the tumour, was
also seen. Hybridisation with pCGa and pHC36 proved
uninformative. RFLPs demonstrated by hybridisation with
the minisatellite probes AMS31 and ZMS43 showed the
tumour to be heterozygous but with both probes the parents
has one allele in common while hybridisation with )MSI
showed the tumour to be homozygous for one of the
paternal alleles.
Y chromosome-specific sequences
No hybridisation with the Y chromosome-specific probe
CY84 was seen in either tumour (Figure 3) indicating the
sex of both tumours to be female. Filters negative for Y
chromosome-specific sequences were shown to have
hybridisable DNA in the negative tracks by demonstrating
the presence of bands in all tracks when the same filters were
hybridised with pCGa.
Discussion
Cytogenetic studies have previously been made of a small
number of choriocarcinomas. Early studies of direct pre-
parations (Galton et al., 1963; Makino et al., 1965), studies
of tumours grown in xenografts (Wake et al., 1981; Lawler
& Fisher, 1986) and of established cell lines (Sasaki et al.,
1982; Sekiya et al., 1983; Okabe et al., 1983; Sheppard et al.,
1985) showed the tumours to be aneuploid most having
karyotypes in the hyperdiploid or hypotetraploid range. All
karyotypes showed abnormalities including gains, losses and
chromosomal rearrangements.
Studies of the tumour origin using chromosomal poly-
morphisms have also been made in four choriocarcinoma cell
lines and four cases of tumours grown in xenografts. In two
of the cell lines the antecedent pregnancy was a normal
conception while two had been preceded by HM (Sasaki et
al., 1982). Three of the cases of choriocarcinoma grown in
xenografts had a history of molar pregnancy (Wake et al.,
1981) but in only one case was the immediate antecedent
pregnancy a HM. The fourth case, grown in xenograft was
in a patient who had previously had a spontaneous abortion
Table I RFLPs in parental and tumour tissue
Probe 2MSI AMS31 pAg3 AMS43 pCGa pHC36
Chromosome
localisation ip 7pter-q22 7q31.3-qter 12 6ql2-q21 lipl4-plS
Enzyme Hinfl Hinfl Hinfl Hinfl EcoRI HindIII Taqi
MA
Maternal a ab ab ab 5 4 8,6.5
Tumour c d b c 10 1 6.5
Paternal bc cd bc cd 10 1 8,6.5
FS
Maternal ab ab ab ab 5 4 8,6.5
Tumour d cb cd bc 5 4 6.5
Paternal cd cb cd bc 5 4 6.5
For single copy probes the size of the polymorphic bands are given in kbs, two band sizes
indicating RFLPs for which the parent or tumour was heterozygous. A large number of different
bands of varying size are identified with the minisatellite probes. The letters a, b, c, d are used to
differentiate between different band sizes within a case and do not represent specific
polymorphisms.
Two different polymorphisms are identified by hybridisation of pCGa to EcoRl or HindlIl
digests. However, because of the close linkage of these polymorphisms the results with the probe





Figure 2 RFLPs in case FS detected with pAg3 hybridised to
DNA from maternal lymphocytes (m), tumour tissue (t) and
paternal lymphocytes (p), demonstrating the androgenetic and
heterozygous origin of the tumour. A minor band, corresponding
to the stronger maternal band represents contamination of





Figure 1 RFLPs detected in case MA with (a) probes pCGa
and pHC36 and (b) locus specific minisatellite probes AMS1,
AMS31, pAg3 and AMS43 in DNA from maternal lymphocytes
(m), tumour tissue (t) and paternal lymphocytes (p).
RFLPs detected with pCGa, AMS1, AMS31, and )MS43
demonstrate the androgenetic origin of the tumour while RFLPs
detected with pHC36, AMS1, AMS31, pAg3 and AMS43 demon-
strate the homozygous origin of the tumour. Minor bands seen
in the tumour when hybridised with pCGa, 1MSI and pAg3
correspond to maternal RFLPs and represent contamination of
tumour DNA with DNA from maternal host tissue.
(Lawler & Fisher, 1986). The genetic origin of those chorio-
carcinoma which follow HM are of particular interest in
relation to the increased risk of malignancy following these
pregnancies. A pregnancy with HM carries a relative risk of
progressing to choriocarcinoma in the order of 1,000 times
greater than a normal pregnancy (Bagshawe et al., 1973).
However, the majority of HM do resolve spontaneously and
the identification of patients at risk is clinically important.
Studies of the genetic origin of HM has shown that
patients with PHM rarely require subsequent treatment for
trophoblastic tumours (WHO, 1983; Lawler & Fisher, 1987)
and thus the risk of failure of HM to resolve spontaneously
is associated largely with androgenetic CHM.
In 1980 Kajii suggested that the heterozygous dispermic
complete HM might have the more malignant potential and
Figure 3 CY 84 hybridised to DNA from male and female
controls and tumour tissue demonstrating the absence of Y
chromosome-specific sequences in the tumours MA or FS.
this appeared to be confirmed by Wake et al. (1984) who
found that 3 of 5 (60%) patients with heterozygous CHM
required further treatment while only 5% of those with
homozymous CHM did so. Other reports have not found
any difference between the frequency with which patients
with the two types of HM required subsequent treatment
(Fisher & Lawler, 1984; Lawler & Fisher, 1987). One
difficulty comparing these studies arises because patients are
treated following a clinical rather than histopathological
diagnosis of trophoblastic tumour, based largely on human
chorionic gonadotrophin levels (Bagshawe et al., 1986) and it
is often not known whether the tumour is choriocarcinoma
or benign invasive mole. A histological diagnosis would
usually require hysterectomy which is not often carried out,
both lesions generally responding completely to cytotoxic
therapy.
A different approach to examine the relationship between
the origin and the malignant potential of HM is to examine
choriocarcinoma which follow HM and determine the origin
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Chromosomal polymorphisms have been used to examine
two cell lines (Sasaki et al., 1982; Sheppard et al., 1985) and
one tumour grown in xenograft (Wake et al., 1981) from
post-mole choriocarcinomas. All three were shown to be
heterozygous although parental chromosomes were not
examined in the two cell lines and those studied in the
xenograft uninformative in terms of the origin of the tumour
in relation to parental chromosomes. These studies also
relied on the ability of choriocarcinoma to grow in culture
or as xenografts, conditions under which cells from a
heterozygous tumour might have an advantage, and where
contamination from other cell lines is possible.
In the present study polymorphisms of the DNA itself
were examined, the DNA being made directly from the
primary tumour so eliminating any bias which might be
introduced by cell culture. Informative polymorphisms in
both parents were also examined, particular use being made
of the hypervariable minisatellite probes in order to
distinguish between maternal and paternal genetic
contributions to the tumour. All bands seen in the tumours
were compatible with their having an androgenetic origin
and in several instances this was the only possible origin,
thus confirming that the causative pregnancy was with a
CHM. Using the hypervariable minisatellite probes we have
previously shown that choriocarcinoma which follow normal
pregnancies have both paternal and maternal polymorphisms
(unpublished observations).
Although both tumours in the present study were
androgenetic in origin, they differed in that one (FS) showed
both heterozygous and homozygous patterns of RFLPs
where the father was informative, while the other (MA)
showed only homozygosity for the paternal RFLPs. In the
tumour FS, a homozygous band was identified by )MS1.
Similarly the absence of Y chromosome-specific sequence
suggests homozygosity of the sex chromosomes. However,
pAg3 identified both paternal bands in the tumour showing it
to be heterozygous. This pattern of markers suggests that this
tumour followed a HM which had arisen by dispermy or a
failure ofmeiosis I or II in the sperm. Further polymorphisms
close to the centromere would be needed to distinguish these
possibilities although previous reports in which the origin of
heterozygous CHM have been examined have shown them to
be dispermic (Ohama et al., 1981; Surti et al., 1982; Fisher et
al., 1984; Wake et al., 1984).
The tumour MA was examined with six informative
probes, five for autosomal and one for sex chromosome
polymorphisms. In each case the tumour was shown to be
homozygous. It has become increasingly recognized that
some tumours show loss of heterozygosity. Early studies of
childhood tumours for example showed loss of chromosome
13 material in retinoblastomas (Cavenee et al., 1983) while
more recently similar losses have been shown in common
cancers, chromosome 5 loss for example being demonstrated
in colon cancers (Solomon et al., 1987). However, this loss is
generally specific, affecting only one particular chromosome
in tumours of the same type. No specific chromosomal
rearrangement has yet been identified in choriocarcinoma
(Sheppard et al., 1985).
Although an origin by dispermy cannot be excluded in
tumours such as MA, where all informative markers are
homozygous, dispermy becomes statistically unlikely when
sufficient informative unlinked polymorphisms are examined.
If a single informative paternal marker is studied the
probability of fertilisation by two sperm sharing identical
alleles, resulting in the CHM being homozygous is 50%. If
two such markers are examined the probability of a
dispermic CHM being homozygous for both markers
becomes 0.52 (i.e. P=0.25). For six such markers the
probability of the CHM being dispermic becomes 0.016.
Thus the most likely origin of the tumour MA is progression
from a CHM which has arisen by fertilisation of an
anucleate egg by a single sperm which has duplicated.
Although studies of the origin of more choriocarcinomas
following molar pregnancies are needed to determine
whether a patient with a homozygous or heterozygous HM
is at greater risk of developing a choriocarcinoma we have
been able to show that both types of HM, not only, as has
been previously suggested, the heterozygous HM, are
capable of progressing to choriocarcinomas.
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